Skip to main content
Premium Trial:

Request an Annual Quote

Steve Fodor, Peter Wagner, Robert Monaghan, J. Stark Thompson, Andrew Carr, Joel McComb

Premium

Steve Fodor, chairman and CEO of Affymetrix, will receive the 2005 ABRF Award from the Association of Biomolecular Resource Facilities at the organization’s annual meeting in Savannah, Ga., in February 2005.


Zymomyx has named Peter Wagner as its new CEO. He has served as chief technology officer of Zyomyx since 1998 and is a founder of the firm. Wagner succeeds Robert Monaghan.


Gene Logic has elected J. Stark Thompson as non-executive chairman of the board. The election follows the creation of two new management positions and stems from Gene Logic’s decision to “separate the roles of chairman and CEO,” the company said. Thompson was formerly president and CEO of Life Technologies.


Andrew Carr, former president of discovery systems for GE Healthcare, is now functioning in an advisory role within the company. Carr was replaced by Joel McComb in August, who joined the company from a position as president and CEO of Innovadyne Technologies. McComb’s previous work experience included heading the primary care division of Beckman Coulter.

The Scan

Genome Sequences Reveal Range Mutations in Induced Pluripotent Stem Cells

Researchers in Nature Genetics detect somatic mutation variation across iPSCs generated from blood or skin fibroblast cell sources, along with selection for BCOR gene mutations.

Researchers Reprogram Plant Roots With Synthetic Genetic Circuit Strategy

Root gene expression was altered with the help of genetic circuits built around a series of synthetic transcriptional regulators in the Nicotiana benthamiana plant in a Science paper.

Infectious Disease Tracking Study Compares Genome Sequencing Approaches

Researchers in BMC Genomics see advantages for capture-based Illumina sequencing and amplicon-based sequencing on the Nanopore instrument, depending on the situation or samples available.

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.